Current  ||| S:0 E:8 ||| JJ
antihyperglycemic  ||| S:8 E:26 ||| JJ
treatment  ||| S:26 E:36 ||| NN
strategies  ||| S:36 E:47 ||| NNS
for  ||| S:47 E:51 ||| IN
patients  ||| S:51 E:60 ||| NNS
with  ||| S:60 E:65 ||| IN
type  ||| S:65 E:70 ||| NN
2  ||| S:70 E:72 ||| CD
diabetes  ||| S:72 E:81 ||| NN
mellitus  ||| S:81 E:90 ||| VBD
The  ||| S:90 E:94 ||| DT
current  ||| S:94 E:102 ||| JJ
epidemics  ||| S:102 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
excessive  ||| S:115 E:125 ||| JJ
weight  ||| S:125 E:132 ||| NN
and  ||| S:132 E:136 ||| CC
type  ||| S:136 E:141 ||| NN
2  ||| S:141 E:143 ||| CD
diabetes  ||| S:143 E:152 ||| NN
mellitus  ||| S:152 E:161 ||| NNS
( ||| S:161 E:162 ||| -LRB-
T2DM ||| S:162 E:166 ||| NNP
)  ||| S:166 E:168 ||| -RRB-
cause  ||| S:168 E:174 ||| VB
significant  ||| S:174 E:186 ||| JJ
morbidity  ||| S:186 E:196 ||| NN
and  ||| S:196 E:200 ||| CC
mortality ||| S:200 E:209 ||| NN
.  ||| S:209 E:211 ||| .
T2DM  ||| S:211 E:216 ||| NNP
frequently  ||| S:216 E:227 ||| RB
coexists  ||| S:227 E:236 ||| VBN
with  ||| S:236 E:241 ||| IN
excess  ||| S:241 E:248 ||| JJ
weight  ||| S:248 E:255 ||| NN
as  ||| S:255 E:258 ||| IN
well  ||| S:258 E:263 ||| RB
as  ||| S:263 E:266 ||| IN
hypertension  ||| S:266 E:279 ||| NN
and  ||| S:279 E:283 ||| CC
dyslipidemia ||| S:283 E:295 ||| NN
,  ||| S:295 E:297 ||| ,
placing  ||| S:297 E:305 ||| VBG
a  ||| S:305 E:307 ||| DT
significant  ||| S:307 E:319 ||| JJ
percentage  ||| S:319 E:330 ||| NN
of  ||| S:330 E:333 ||| IN
the  ||| S:333 E:337 ||| DT
population  ||| S:337 E:348 ||| NN
at  ||| S:348 E:351 ||| IN
an  ||| S:351 E:354 ||| DT
elevated  ||| S:354 E:363 ||| JJ
risk  ||| S:363 E:368 ||| NN
of  ||| S:368 E:371 ||| IN
cardiovascular  ||| S:371 E:386 ||| JJ
disease ||| S:386 E:393 ||| NN
.  ||| S:393 E:395 ||| .
Maintaining  ||| S:395 E:407 ||| VBG
effective  ||| S:407 E:417 ||| JJ
glycemic  ||| S:417 E:426 ||| JJ
control  ||| S:426 E:434 ||| NN
is  ||| S:434 E:437 ||| VBZ
linked  ||| S:437 E:444 ||| VBN
with  ||| S:444 E:449 ||| IN
a  ||| S:449 E:451 ||| DT
diminished  ||| S:451 E:462 ||| JJ
risk  ||| S:462 E:467 ||| NN
of  ||| S:467 E:470 ||| IN
developing  ||| S:470 E:481 ||| VBG
microvascular  ||| S:481 E:495 ||| JJ
complications ||| S:495 E:508 ||| NNS
,  ||| S:508 E:510 ||| ,
and  ||| S:510 E:514 ||| CC
recent  ||| S:514 E:521 ||| JJ
studies  ||| S:521 E:529 ||| NNS
have  ||| S:529 E:534 ||| VBP
shown  ||| S:534 E:540 ||| VBN
it  ||| S:540 E:543 ||| PRP
may  ||| S:543 E:547 ||| MD
also  ||| S:547 E:552 ||| RB
reduce  ||| S:552 E:559 ||| VB
overall  ||| S:559 E:567 ||| JJ
macro  ||| S:567 E:573 ||| JJ
vascular  ||| S:573 E:582 ||| JJ
complications ||| S:582 E:595 ||| NNS
.  ||| S:595 E:597 ||| .
Reduction  ||| S:597 E:607 ||| NN
of  ||| S:607 E:610 ||| IN
associated  ||| S:610 E:621 ||| JJ
risk  ||| S:621 E:626 ||| NN
factors ||| S:626 E:633 ||| NNS
,  ||| S:633 E:635 ||| ,
including  ||| S:635 E:645 ||| VBG
those  ||| S:645 E:651 ||| DT
related  ||| S:651 E:659 ||| VBN
to  ||| S:659 E:662 ||| TO
excessive  ||| S:662 E:672 ||| JJ
weight ||| S:672 E:678 ||| NN
,  ||| S:678 E:680 ||| ,
high  ||| S:680 E:685 ||| JJ
blood  ||| S:685 E:691 ||| NN
pressure ||| S:691 E:699 ||| NN
,  ||| S:699 E:701 ||| ,
and  ||| S:701 E:705 ||| CC
dyslipidemia ||| S:705 E:717 ||| NN
,  ||| S:717 E:719 ||| ,
are  ||| S:719 E:723 ||| VBP
also  ||| S:723 E:728 ||| RB
necessary  ||| S:728 E:738 ||| JJ
to  ||| S:738 E:741 ||| TO
meaningfully  ||| S:741 E:754 ||| RB
decrease  ||| S:754 E:763 ||| VB
cardiovascular  ||| S:763 E:778 ||| JJ
risk ||| S:778 E:782 ||| NN
.  ||| S:782 E:784 ||| .
Agents  ||| S:784 E:791 ||| NNS
that  ||| S:791 E:796 ||| WDT
can  ||| S:796 E:800 ||| MD
improve  ||| S:800 E:808 ||| VB
glycemia  ||| S:808 E:817 ||| VBN
with  ||| S:817 E:822 ||| IN
weight  ||| S:822 E:829 ||| NN
neutrality  ||| S:829 E:840 ||| NNS
or  ||| S:840 E:843 ||| CC
weight  ||| S:843 E:850 ||| NN
loss  ||| S:850 E:855 ||| NN
could  ||| S:855 E:861 ||| MD
offer  ||| S:861 E:867 ||| VB
additional  ||| S:867 E:878 ||| JJ
benefit  ||| S:878 E:886 ||| NN
to  ||| S:886 E:889 ||| TO
overweight  ||| S:889 E:900 ||| VB
patients  ||| S:900 E:909 ||| NNS
with  ||| S:909 E:914 ||| IN
T2DM ||| S:914 E:918 ||| CD
.  ||| S:918 E:920 ||| .
Although  ||| S:920 E:929 ||| IN
the  ||| S:929 E:933 ||| DT
major  ||| S:933 E:939 ||| JJ
pathophysiologic  ||| S:939 E:956 ||| JJ
defects  ||| S:956 E:964 ||| NNS
in  ||| S:964 E:967 ||| IN
T2DM  ||| S:967 E:972 ||| NNP
are  ||| S:972 E:976 ||| VBP
recognized  ||| S:976 E:987 ||| VBN
to  ||| S:987 E:990 ||| TO
be  ||| S:990 E:993 ||| VB
beta-cell  ||| S:993 E:1003 ||| JJ
dysfunction  ||| S:1003 E:1015 ||| NN
and  ||| S:1015 E:1019 ||| CC
peripheral  ||| S:1019 E:1030 ||| JJ
insulin  ||| S:1030 E:1038 ||| NN
resistance ||| S:1038 E:1048 ||| NN
,  ||| S:1048 E:1050 ||| ,
derangements  ||| S:1050 E:1063 ||| VBG
in  ||| S:1063 E:1066 ||| IN
the  ||| S:1066 E:1070 ||| DT
incretin  ||| S:1070 E:1079 ||| JJ
system  ||| S:1079 E:1086 ||| NN
may  ||| S:1086 E:1090 ||| MD
contribute  ||| S:1090 E:1101 ||| VB
as  ||| S:1101 E:1104 ||| RB
well ||| S:1104 E:1108 ||| RB
.  ||| S:1108 E:1110 ||| .
Antidiabetes  ||| S:1110 E:1123 ||| JJ
agents  ||| S:1123 E:1130 ||| NNS
targeting  ||| S:1130 E:1140 ||| VBG
this  ||| S:1140 E:1145 ||| DT
system  ||| S:1145 E:1152 ||| NN
include  ||| S:1152 E:1160 ||| VBP
dipeptidyl  ||| S:1160 E:1171 ||| JJ
peptidase-4  ||| S:1171 E:1183 ||| NNP
( ||| S:1183 E:1184 ||| -LRB-
DPP-4 ||| S:1184 E:1189 ||| NNP
)  ||| S:1189 E:1191 ||| -RRB-
inhibitors  ||| S:1191 E:1202 ||| NN
and  ||| S:1202 E:1206 ||| CC
glucagon-like  ||| S:1206 E:1220 ||| NNP
peptide-1  ||| S:1220 E:1230 ||| NNP
( ||| S:1230 E:1231 ||| -LRB-
GLP-1 ||| S:1231 E:1236 ||| NNP
)  ||| S:1236 E:1238 ||| -RRB-
receptor  ||| S:1238 E:1247 ||| NN
agonists ||| S:1247 E:1255 ||| NN
.  ||| S:1255 E:1257 ||| .
Both  ||| S:1257 E:1262 ||| DT
classes  ||| S:1262 E:1270 ||| NNS
have  ||| S:1270 E:1275 ||| VBP
been  ||| S:1275 E:1280 ||| VBN
shown  ||| S:1280 E:1286 ||| VBN
to  ||| S:1286 E:1289 ||| TO
significantly  ||| S:1289 E:1303 ||| RB
reduce  ||| S:1303 E:1310 ||| VB
hyperglycemia ||| S:1310 E:1323 ||| NNS
.  ||| S:1323 E:1325 ||| .
GLP-1  ||| S:1325 E:1331 ||| NNP
receptor  ||| S:1331 E:1340 ||| NN
agonists  ||| S:1340 E:1349 ||| VBZ
also  ||| S:1349 E:1354 ||| RB
promote  ||| S:1354 E:1362 ||| VB
significant  ||| S:1362 E:1374 ||| JJ
weight  ||| S:1374 E:1381 ||| NN
loss  ||| S:1381 E:1386 ||| NN
and  ||| S:1386 E:1390 ||| CC
have  ||| S:1390 E:1395 ||| VBP
potentially  ||| S:1395 E:1407 ||| RB
beneficial  ||| S:1407 E:1418 ||| JJ
effects  ||| S:1418 E:1426 ||| NNS
on  ||| S:1426 E:1429 ||| IN
cardiovascular  ||| S:1429 E:1444 ||| JJ
risk  ||| S:1444 E:1449 ||| NN
markers ||| S:1449 E:1456 ||| NN
.  ||| S:1456 E:1458 ||| .
